Janus kinase inhibitors and uses thereof
US10017477B2 · kind B2 · utility
17Cited by
63References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2015 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Apr 23, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides kinase inhibitors, such as compounds of Formula (I) and Formula (II). The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). Also provided are pharmaceutical compositions, kits, methods, and uses that involve the compounds for reducing the activity of a kinase and/or treating and/or preventing a condition associated with aberrant activity of a kinase (e.g., a proliferative disease, inflammatory disorder, autoimmune disorder, painful condition, and/or viral infection). (I) (II)
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.